Drugs / Anti-GD2-CAR engineered T cells
Anti-GD2-CAR engineered T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02107963 | Feb 2014 → Aug 2016 | melanoma, neuroblastoma, osteosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-GD2-CAR engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02107963 ↗ |
| Known as | anti-GD2-CAR T cells | “Patients will be monitored for toxicity, antitumor effects and persistence of anti-GD2-CAR T cells.” NCT02107963 ↗ |
| Known as | GD2-CAR.OX40.28.z.iC9 | “We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of administration in children and young adults with...” PMID 38134936 ↗ Dec 2023 |
| Known as | GD2-CAR.OX40.28.z.ICD9 | “A 3rd generation anti-GD2-CAR (GD2-CAR.OX40.28.z.ICD9) has been produced and holds promise for increased activity compared to the 1st generation GD2-CAR already studied in...” NCT02107963 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors.” PMID 38134936 ↗ Dec 2023 |